Aethlon Medical Agrees To Acquire Syngen Research.

SAN DIEGO--(BW HealthWire)--Oct. 12, 1999--

Aethlon Medical Inc., (formally known as Bishop Equities Inc.) (OTCBB:BSEQ) announced today that it has entered into a letter of intent to acquire Syngen Research of San Diego.

Syngen Research provides independent research and consulting services to a number of high profile biotechnology companies. Under the direction of Richard Tullis, Ph.D., the company has also developed novel and proprietary DNA amplification and protein signal amplification technologies for use within the medical diagnostics industry.

Regarding the acquisition of Syngen Research, James A. Joyce, chairman of Aethlon Medical stated: "The Syngen Research acquisition adds two exciting technologies to the Aethlon Medical portfolio and establishes a laboratory presence in San Diego which will complement the activities of our operations in Buffalo, N.Y. Furthermore, we are particularly pleased to have Dr. Tullis, who is a highly respected scientist and business personality, join the Aethlon Medical team." The acquisition is scheduled to close prior to Nov. 30, 1999.

About Aethlon Medical

Aethlon Medical is in the business of acquiring proprietary medical device technologies that can be developed and commercialized on an international basis. The first step in this strategy was initiated through the recent acquisition of Hemex Inc. Hemex has developed a proprietary platform technology known as the Hemopurifier, a device that effectively removes targeted intoxicants from the blood without side effects.

The first family of Hemopurifiers to be commercialized has been developed for the purpose of removing harmful metal intoxicants, including, iron, lead, and aluminum. Medical conditions associated with metal intoxication in the body include: cardiovascular disease, permanent organ damage (kidneys, liver), brain damage, impotence in men, early menopause in women, diabetes, and arthritis.

Cisplatin, an effective but toxic chemotherapeutic agent for treating many forms of cancer, is another intoxicant that can be removed by the Hemopurifier. The side effects associated with the toxicity of Cisplatin are well documented. Future products in the development pipeline include Hemopurifiers designed to remove: (a.) various viruses; (b.) plutonium; and, (c.) drug overdoses.

The Hemopurifier is protected by patents in the United States, Europe, and Japan, with additional patents pending. The Hemopurifier is a disposable product which has been designed for use in an established network of dialysis and plasmapherisis machines located at approximately 6000 hospitals, 2000 freestanding dialysis centers, and 100 regional poison control centers throughout the U.S.

Leading participants within the dialysis industry segment include: Baxter International Inc. (NYSE:BAX), Fresenius Medical Care (NYSE:FMS), Renal Care Group Inc. (Nasdaq:RCGI), Minntech Corp. (Nasdaq:MNTX), Renex Corp. (Nasdaq:RENX), Total Renal Care (NYSE:TRL). Aethlon Medical's Web site may be viewed at http://www.aethlonmedical.com.